Identifiants & Marche
Ticker
MLTX
ISIN
KY61559X1045
CIK
0001821586
Bourse
NASDAQ
Devise
USD
Entreprise
Pays
CH
Siege
N/A
Fondee
N/A
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.